Current Edition

age-related macular degeneration

FDA greenlights Genentech’s eye implant for macular degeneration. Will it be a tough sell?

Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants. That’s the stigma Genentech will potentially face as it …

Continue Reading →

Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment

Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies …

Continue Reading →